Literature DB >> 8784462

p53 alterations in chemically induced hamster cheek-pouch lesions.

I B Gimenez-Conti1, M LaBate, F Liu, E Osterndorff.   

Abstract

To confirm that the hamster cheek-pouch carcinogenesis model reflects development of human squamous cell carcinoma (SCC), we determined if and when p53 mutations occur in the development of SCC in this model by using immunohistochemical staining and polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) analysis plus direct DNA sequencing. Twenty-four hamster cheek-pouches were treated with a solution of 0.5% 7,12-dimethylbenz[a]anthracene in mineral oil three times a week for 16 wk. The malignant endophytic and exophytic tumors induced with this protocol are preceded by a sequence of premalignant lesions such as hyperplasia with or without dysplasia and carcinoma in situ, similar to the development of this cancer in humans. For this study, p53 protein accumulation was evaluated by immunostaining of various hamster cheek-pouch exophytic and endophytic SCCs as well as flat dysplastic hyperplasia and carcinomas in situ. A moderate percentage (33.3%) of exophytic lesions and most endophytic carcinomas (90%) showed positive p53 staining. In addition we also found p53-positive staining in a number of preneoplastic lesions, including areas of focal hyperplasia, dysplastic hyperplasia, and carcinomas in situ. To determine whether the alterations in p53 staining were due to p53 gene mutation, we used PCR-SSCP analysis and direct sequencing. PCR products corresponding to exons 5a, 6, 7, and 8 from 40 tumors with the highest percentage of p53-stained cells were analyzed. We detected shifted bands in 17 lesions. Direct sequencing of eight selected shifted bands revealed four mutations, including two G-->T transversions in codons 216 (tumor #1) and 252 (tumor #2) and one G-->C transversion in codon 282 (tumor #3). Tumor #4 contained a frameshift mutation in codon 251. These mutations are consistent with those reported in many human cancers. Therefore, we concluded that in the hamster cheek-pouch model, p53 protein accumulation occurs frequently and early in carcinogenesis, as it does in human SCCs, and some of these p53 alterations are due to p53 gene mutations. These findings may help us better define the mechanisms of carcinogenesis in the hamster cheek-pouch model, and p53 alterations may be an early biomarker of progression for chemoprevention studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784462     DOI: 10.1002/(SICI)1098-2744(199608)16:4<197::AID-MC3>3.0.CO;2-D

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.

Authors:  Peiying Yang; Zheng Sun; Diana Chan; Carrie A Cartwright; Mary Vijjeswarapu; Jibin Ding; Xiaoxin Chen; Robert A Newman
Journal:  Carcinogenesis       Date:  2008-08-06       Impact factor: 4.944

2.  Differential expression of p53, p63 and p73 protein and mRNA for DMBA-induced hamster buccal-pouch squamous-cell carcinomas.

Authors:  Yuk-Kwan Chen; Shue-Sang Huse; Li-Min Lin
Journal:  Int J Exp Pathol       Date:  2004-04       Impact factor: 1.925

3.  Tumor suppressor p16(INK4A)/Cdkn2a alterations in 7, 12-dimethylbenz(a)anthracene (DMBA)-induced hamster cheek pouch tumors.

Authors:  Junan Li; Blake Warner; Bruce C Casto; Thomas J Knobloch; Christopher M Weghorst
Journal:  Mol Carcinog       Date:  2008-10       Impact factor: 4.784

4.  Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis.

Authors:  Kuppusamy Panjamurthy; Shanmugam Manoharan; Madhavan Ramados Nirmal; Lakshmanan Vellaichamy
Journal:  Invest New Drugs       Date:  2008-11-14       Impact factor: 3.850

5.  Perchloric acid-soluble proteins from goat liver inhibit chemical carcinogenesis of Syrian hamster cheek-pouch carcinoma.

Authors:  F Ghezzo; G N Berta; B Bussolati; A Bosio; G Corvetti; F Di Carlo; G Bussolati; R Guglielmone; A Bartorelli
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.